The global demand for Transplant Drug Monitoring Assay Market is presumed to reach the market size of nearly USD 465.34 MN by 2028 from USD 210.5 MN in 2021 with a CAGR of 12% under the study period 2022 - 2028.
Transplant drug monitoring assay is crucial in helping health care professionals maintain plasma and blood levels of immunosuppressants within their respective therapeutic ranges. Transplant drug monitoring assay starts with the initiation of medication. It includes the determination of a preliminary dosage regimen acceptable for the patient and clinical state characteristics such as age, body mass index, weight, organ function and drug therapy.
Market Dynamics
The factors fueling the market growth are the increased demand for organ transplants, increased R&D funding, and an increase in the prevalence of chronic diseases such as kidney diseases. Moreover, an increase in the need for point-of-care therapeutic drug monitoring and home-based therapeutic drug monitoring is likely to offer lucrative market opportunities for players operating in the global transplant drug monitoring assay industry during the forecast period. Additionally, a rise in healthcare expenditure, improvement in healthcare infrastructure, increase in global per capita income, and government reimbursement programs are projected to present profitable prospects in the transplant drug monitoring assay market in the upcoming years. However, the need for huge investments and the reluctance of small hospitals to offer transplant drug monitoring assay services may hamper the market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of transplant drug monitoring assay. The growth and trends of transplant drug monitoring assay industry provide a holistic approach to this study.
Market Segmentation
This section of the transplant drug monitoring assay market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Product
- Equipment
- Consumables (Chromatography & Ms Detectors, Immunoassay Analyzers, Clinical Chemistry Analyzers)
By Technology
- Chromatography-Ms
- Immunoassays
By Drug
- Tacrolimus
- Methotrexate
- Cyclosporin
- Others
By End-User
- Hospital Laboratories
- Commercial & Private Laboratories
- Others
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Transplant Drug Monitoring Assay market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Transplant Drug Monitoring Assay Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the transplant drug monitoring assay market include Abbott, Thermo Fisher Scientific Inc., H.U. Group Holdings Inc. (Fujirebio Holdings, Inc.), Hoffmann-La Roche Ltd., Siemens Healthineers AG, Hologic Inc., Danaher Corporation, Bio-Rad Laboratories Inc., Other prominent players. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
